KMPH KemPharm, Inc.

4.50
+0  (3%)
Previous Close 4.35
Open 4.40
Price To book 0.00
Market Cap 65.91M
Shares 14,646,000
Volume 18,061
Short Ratio 13.70
Av. Daily Volume 37,310

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 complete. NDA filing due 2019.
KP511/IR 511/ER
Severe pain
Phase 1 trial completed. Further trials to commence 1H 2017, with data end of 2017. NDA filing 2018.
KP201/IR
Acute pain
Phase 1 trial completed December 2016. Efficacy trials to commence 2H 2017, with data 1H 2018.
KP415
ADHD
CRL issued November 2015. Appeal against FDA launched November 2016.
KP201/APAP
Acute pain.

Latest News

  1. KemPharm to Present at the 2nd Annual Neuroscience Biopartnering and Investment Forum
  2. KemPharm Presents Clinical Data for Opioid Prodrug Candidates at American Academy of Pain Medicine’s Annual Meeting
  3. Can The Uptrend Continue for KemPharm (KMPH)?
  4. KemPharma reports 4Q loss
  5. KemPharm, Inc. Reports Fourth Quarter and Year End 2016 Results
  6. KemPharm, Inc. to Report Fourth Quarter and Year End 2016 Results
  7. KemPharm Announces Additional Patent Protection for Prodrug Portfolio
  8. KemPharm to Present at Upcoming Investor Conferences
  9. SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of KemPharm, Inc. and Advises Investors with Losses to Contact the Firm
  10. Lifshitz & Miller LLP Announces Investigation of Dr. Reddy's Laboratories Limited, Exterran Corporation, Gigamon Inc., KemPharm, Inc., Navient Corporation, NCI, Inc., Opus Bank, PixarBio Corporation and Yahoo! Inc.
  11. CRITICAL INVESTOR ALERT: Khang & Khang LLP Announces an Investigation of KemPharm, Inc. and Encourages Investors with Losses to Contact the Firm
  12. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of KemPharm, Inc. - KMPH
  13. Shareholder Alert: Lundin Law PC Announces an Investigation of KemPharm, Inc. and Encourages Investors with Losses to Contact the Firm
  14. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of KemPharm, Inc. (KMPH)
  15. KEMPHARM NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Significant Losses Investing In KemPharm, Inc. To Contact The Firm
  16. Robbins Arroyo LLP: KemPharm, Inc. (KMPH) Misled Shareholders According to a Recently Filed Class Action
  17. KemPharm CEO On Recent Results, Catalysts And Prospects: 'ADHD Is By Far The Larger Market Opportunity'